🔎 Trials Near Me

홈 › 버킷 림프종 › 인디애나

인디애나의 버킷 림프종 임상 시험

버킷 림프종 관련 연구 6개가 인디애나 내 여러 지역에서 참여자를 모집하고 있습니다.

인디애나의 도시

공식 연구 텍스트(영어)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Riley Hospital for Children, Indianapolis
피험자 모집 중2상
366 Days – 46 Years · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Riley Hospital for Children, Indianapolis
피험자 모집 중2상
365 Days · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Indiana University Health Arnett, Inc., Lafayette
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT07648264

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Riley Hospital for Children, Indianapolis
피험자 모집 중2상
1세 ~ 30세 · 모든 성별 · 2026. 9. 1. 업데이트됨 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Riley Hospital for Children, Indianapolis
  • Ascension Saint Vincent Indianapolis Hospital, Indianapolis
피험자 모집 중3상
365 Days – 25 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT03959085

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • Riley Hospital for Children - Indiana University, Indianapolis
피험자 모집 중2상
1세 ~ 25세 · 모든 성별 · 2025. 5. 4. 업데이트됨 · NCT03509961

ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.